What question did this study set out to answer?

The aim was to compare the efficacy of acalabrutinib and the venetoclax-obinutuzumab combination in treatment-naive CLL patients.

June 7, 2026Cancer MedicineOpen Access

Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment‐Naive Chronic Lymphocytic Leukemia: A Real‐World Propensity Score‐Matched Study

View Full Paper

Ask AI

Bookmark

The aim was to compare the efficacy of acalabrutinib and the venetoclax-obinutuzumab combination in treatment-naive CLL patients.
Retrospective analysis using the TriNetX global database.
669 treatment-naïve patients with TP53-unmutated CLL matched 1:1 using propensity score matching.
Primary endpoint was time to next treatment (TTNT); secondary endpoints included overall survival and adverse events.
Venetoclax plus obinutuzumab resulted in longer TTNT (median not reached vs. 47.7 months).
Improved 4-year overall survival observed with the venetoclax regimen.
Higher rates of cytopenias and infections were recorded with venetoclax compared to acalabrutinib.

No takes yet. Share an insight, caveat, or question.

Real-world study compares TTNT and OS for CLL treatments, indicating venetoclax's superior outcomes.

Liao et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark